Subject(s)
COVID-19 , Lymphadenopathy , Humans , COVID-19 Vaccines , Vaccination , Primary Health CareABSTRACT
The relation between infections and autoimmune diseases has been extensively investigated. Multiple studies suggest a causal relation between these two entities with molecular mimicry, hyperstimulation and dysregulation of the immune system as plausible mechanisms. The recent pandemic with a new virus, i.e., SARS-CoV-2, has resulted in numerous studies addressing the potential of this virus to induce autoimmunity and, eventually, autoimmune disease. In addition, it has also revealed that pre-existing auto-immunity (auto-Abs neutralizing type I IFNs) could cause life-threatening disease. Therefore, the topic of the 15th Dresden Symposium on Autoantibodies was focused on autoimmunity in the SARS-CoV-2 era. This report is a collection and distillation of the topics presented at this meeting.
Subject(s)
COVID-19 , RNA, Viral , Autoantibodies , Autoimmunity , Humans , SARS-CoV-2ABSTRACT
The opinion I put forward in this paper is that attention must continue to be paid to clinical observations compatible with a detrimental effect of anti-SARS-CoV-2 in certain diseases of immunological nature. Using the example of the atypical thrombocytopenic thromboses caused by adenoviral-vector-based vaccines, I argue that usual post-marketing pharmacovigilance programs may fail in identifying very rare vaccine-related disorders. Since the robust protective immunity induced by mRNA vaccines is related to their distinct capacity to induce strong stimulation of T follicular helper cells, I suggest that the safety of mRNA vaccines should be further assessed by appropriately designed epidemiological and mechanistic studies focusing on lymphoproliferative and autoimmune diseases in which T follicular helper cells were found to play a key role.
ABSTRACT
Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein, we report and discuss unexpected rapid progression of lymphomatous lesions after administration of a BNT162b2 mRNA vaccine booster in a man recently diagnosed with AITL.
ABSTRACT
Michel Goldman and Cédric Hermans discuss thrombotic mechanisms in COVID-19 and rare adverse reactions to SARS-CoV-2 vaccinations.
Subject(s)
Autoantibodies/immunology , Autoimmunity , COVID-19 Vaccines/adverse effects , COVID-19/immunology , COVID-19/therapy , Platelet Factor 4/immunology , Purpura, Thrombocytopenic, Idiopathic/immunology , SARS-CoV-2/immunology , Animals , COVID-19/virology , ChAdOx1 nCoV-19 , Host-Pathogen Interactions , Humans , Purpura, Thrombocytopenic, Idiopathic/virology , Risk Assessment , Risk Factors , SARS-CoV-2/pathogenicity , Vaccination/adverse effectsABSTRACT
Clinical trials to identify efficient treatments against COVID-19 flourish worldwide without much attention to patients' voice so far. As therapeutic interventions in the early phase of the disease are attracting more and more interest, we argue that now is the time to involve patients' organizations in the design of clinical protocols in order to define the most relevant end-points and assess the risk-benefit balance of new therapies.
Subject(s)
Coronavirus Infections/prevention & control , Decision Making , Government , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Quarantine/methods , Quarantine/organization & administration , Social Responsibility , Strategic Planning/standards , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques/methods , Contact Tracing/legislation & jurisprudence , Contact Tracing/methods , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Coronavirus Infections/transmission , Decision Making/ethics , Decision Making/physiology , Government Employees/psychology , Government Regulation , Health Risk Behaviors , Humans , Pneumonia, Viral/epidemiology , Pneumonia, Viral/transmission , Politics , Risk Reduction Behavior , Social IsolationABSTRACT
Michel Goldman and colleagues call on the European medical and scientific community to coordinate efforts on immunotherapy-based approaches to coronavirus.